Transgender people use hormone to increase their interest in and discomfort with sexual activity.

Important insights:

• Participants who were now using testosterone were more interested in having sex and experienced more vaginal discomfort.
• The majority of participants reported experiencing reproductive problems and/or discomfort while having sex.

According to scientists, the use of hormone among trans men and people of different genders was associated with increased interest in sexual activity as well as pain or discomfort while sexually active.

Diana M. Tordoff, PhD, MPH, postdoctoral researcher at the Stanford University School of Medicine, and colleagues wrote,” There is little study on the physical performance of transgender people and gender-dividend folks assigned female at birth.” What is known suggests that, despite the fact that testosterone gender-affirming hormone therapy is linked to increased desire and intimacy, many transgender men also reported dysmenorrhea, an early sign of vaginal atrophy.

Data from 1, 219 transgender men and gender-discriminate individuals ( median age, 27.1 years ) aged 18 to 72 years were used in a cross-sectional analysis by Tordoff and colleagues that was published in the American Journal of Obstetrics &amp, Gynecology. All participants in the PRIDE study —an online, prospective, longitudinal cohort study involving sexual and gender minority people in America—were assigned to be female at birth and were divided into three groups: never ( n = 516 ), current ( N = 602 ), and former ( sin = 76 ). Eight Patient-Reported Outcomes Measurement Information System ( PROMIS ) domains of sexual function and satisfaction were examined by researchers.

The average time spent using cortisol was 37.7 times. In the analysis, 68.9 % of participants said they had had sex in the previous 12 months, 59.5 percent claimed to be in a relationship, and 89.5 % admitted to engaging in any form of sexual activity, such as masturbation. 64.6 % of participants at this time reported experiencing pelvic pain and/or distress while engaging in sexual activity. The vagina/frontal genital opening ( 52.2 % ), the clitoris ( 29.1 % ), and the labia ( 24.5 % ) reported pain and/or discomfort the most frequently.

Compared to never- and former users, current testosterone users reported greater interest in sexual activity ( beta = 6.32 ) and more vaginal pain and/or discomfort.

There were no correlations between existing testosterone use and sexual life satisfaction, stimulation, alveolar pain, discomfort, or orgasm pleasure.

According to the researchers, there is a complex relationship between receiving hormone gender-affirming hormone treatment and physical work that probably includes both physiological and psychological factors. However, given the high prevalence of dyspareunia among transgender people who are given sexual births, it is necessary to evaluate how it affects overall quality of life, find effective and appropriate interventions, and lessen barriers to treatment for these individuals.